June 30, 2021
TALDE PRIVATE EQUITY and ESPIGA CAPITAL have announced the agreement for the sale of DELTALAB, a European leader in the design, manufacture and distribution of consumables, reagents and laboratory equipment for the Healthcare Diagnostics, Life Sciences Research, Industrial and Food Safety sectors.
TALDE PRIVATE EQUITY, ESPIGA CAPITAL and JOSÉ SÁEZ have reached an agreement to sell DELTALAB to SCG Packaging Public Company Limited (“SCGP”) after the successful development of the Company and having exceeded the objectives established in the business plan at the time of its entry in the capital.
José Sáez, who has been a reference shareholder and top executive of Deltalab for the last fifteen years, and the current management team will continue to be part of the shareholding and lead the Company with the objective of continuing to drive its growth.
The closing of the transaction is pending approval by the National Markets and Competition Commission (CNMC) and the Council of Ministers, as it is subject to foreign investment screening.
Founded in 1976 and headquartered in Rubí, DELTALAB is one of the leading European companies in the design, manufacture and distribution of consumables, reagents and laboratory equipment for the Healthcare Diagnostics, Life Sciences Research, Industrial and Food Safety sectors.
DELTALAB has consolidated its market position over the last 10 years by increasing its revenues from €20MM in 2010 to more than €70MM in 2020, expanding its international presence and developing new high value-added products.
SCGP is part of The Siam Cement Public Company Limited ("SCC"), one of Thailand's largest industrial conglomerates with FY2020 consolidated revenues of USD 13.3 billion and a market capitalization of USD 15.1 billion.
SCGP is the largest integrated packaging and paper company in Southeast Asia, with 2020 consolidated revenues of USD 3.1 billion and a market capitalization of USD 5.9 billion. SCC holds 70% of SCGP's equity.
This acquisition is in line with global megatrends, such as preventive healthcare and an aging society, which require an increasing number of laboratory diagnostic tests. The healthcare and medical supplies industry is a fast-growing segment, with an estimated market size of $26 billion in Europe and $48 billion in Asia Pacific.
SCGP's core focus lies in providing solutions to consumers and strives to grow into customized precision segments. Deltalab establishes the essentials for future expansions in rapidly growing Asia Pacific healthcare market, projected at approximately 7-9% annually. In the longer term, this transaction allows SCGP the footprint to accelerate its higher growth and higher value-added prospects.